ICAM1 ADC for late-stage and refractory TNBC

An antibody-drug conjugate (ADC) targeting ICAM1, a cell surface receptor overexpressed in triple negative breast cancer (TNBC), could help treat the disease, including late-stage and refractory tumors.

An anti-ICAM1 human/mouse chimera antibody, which had previously been shown safety in human rheumatoid arthritis trials, was conjugated with one of four different microtubule inhibitor warheads at drug-antibody ratios (DARs) of about 4, via one of three different linkers, and the resulting panel of ADC candidates was screened in human TNBC cell line killing assays, where they had IC50s in the picomolar range...